New combo therapy aims to fight tough pancreatic cancer
NCT ID NCT06821503
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called LM-108, given with an immunotherapy (penpulimab) and two chemotherapy drugs, in people with advanced pancreatic cancer. The goal is to see if the combination is safe and can shrink tumors or slow the disease. About 72 adults with advanced pancreatic cancer will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LM-108 (a monoclonal antibody that clears certain immune cells) plus penpulimab (an immunotherapy) plus chemotherapy (albumin-bound paclitaxel and gemcitabine)
- What this could lead to
- If it works, this could point toward a new treatment option for advanced pancreatic cancer by combining immunotherapy with chemotherapy.
- What could go wrong
- This is an early-phase trial with only 72 participants, so results may not apply to all patients. The combination may cause serious side effects or fail to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
-
Cancer Hospital Chinese Academy of Medical Science
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 100021, China
-
Chongqing Qeneral Hospital
NOT_YET_RECRUITINGChongqing, Chongqing Municipality, 400013, China
-
Harbin Medical University Cancer Hospital
NOT_YET_RECRUITINGHarbin, Heilongjiang, 150081, China
-
Huazhong University of Science and Technology Tongji Medical College of Huazhong University of Science and Technology
NOT_YET_RECRUITINGWuhan, Hubei, 430000, China
-
Jiangsu Cancer Hospital
NOT_YET_RECRUITINGNanjing, Jiangsu, 210000, China
-
Jiangsu Provincial People's Hospital
NOT_YET_RECRUITINGNanjing, Jiangsu, 210000, China
-
Peking Union Medical College Hospital
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 100005, China
-
The First Affiliated Hospital of China Medical University
NOT_YET_RECRUITINGShenyang, Liaoning, 110000, China
-
The First Affiliated Hospital of Nanchang University
NOT_YET_RECRUITINGNanchang, Jiangxi, 330006, China
-
The First Affiliated Hospital of Naval Medical University
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, 200336, China
-
The First Affiliated Hospital of Xi'an Jiaotong University Medical College
NOT_YET_RECRUITINGXi'an, Shaanxi, 710000, China
-
The First Affiliated Hospital of Zhengzhou University
NOT_YET_RECRUITINGZhengzhou, Henan, 450000, China
-
The Sixth People's Hospital of Shenyang
NOT_YET_RECRUITINGShenyang, Liaoning, 110002, China
-
Tianjin Cancer Hospital Airport Hospital
NOT_YET_RECRUITINGTianjin, Tianjin Municipality, 300000, China
-
Tianjin Medical University Cancer Institute & Hospital
NOT_YET_RECRUITINGTianjin, Tianjin Municipality, 300000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted antibody slow advanced pancreatic cancer?
- New Antibody-Drug combo takes on Hard-to-Treat pancreatic cancer
- New drug targets Hard-to-Treat pancreatic cancer by hitting a common mutation
- Experimental combo targets Hard-to-Treat pancreatic cancer
- Engineered immune cells take aim at a common pancreatic cancer mutation
- Radioactive injection takes on tough pancreatic cancer in early trial